These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26343888)

  • 1. The use of JAK inhibitors for low-risk myelofibrosis.
    Alimam S; McLornan D; Harrison C
    Expert Rev Hematol; 2015 Oct; 8(5):551-3. PubMed ID: 26343888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational Janus kinase inhibitors in development for myelofibrosis.
    Bose P; Abou Zahr A; Verstovsek S
    Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib.
    Becker H; Engelhardt M; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
    Assi R; Verstovsek S; Daver N
    Curr Opin Hematol; 2017 Mar; 24(2):115-124. PubMed ID: 28072602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
    Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
    Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman G; Mascarenhas J
    Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging targeted therapies in myelofibrosis.
    Barosi G
    Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
    Gupta V; Hari P; Hoffman R
    Blood; 2012 Aug; 120(7):1367-79. PubMed ID: 22700718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How many JAK inhibitors in myelofibrosis?
    Ferreira BV; Harrison C
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib: a review of its use in patients with myelofibrosis.
    Plosker GL
    Drugs; 2015 Feb; 75(3):297-308. PubMed ID: 25601187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib for the treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Drugs Today (Barc); 2011 Nov; 47(11):817-27. PubMed ID: 22146225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of myelofibrosis after ruxolitinib failure.
    Bose P; Verstovsek S
    Leuk Lymphoma; 2020 Aug; 61(8):1797-1809. PubMed ID: 32297800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
    Mascarenhas J
    Leuk Lymphoma; 2015; 56(9):2493-7. PubMed ID: 25586607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of JAK inhibition in myelofibrosis and beyond.
    Mascarenhas JO; Cross NC; Mesa RA
    Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
    Marchetti M; Barosi G; Cervantes F; Birgegård G; Griesshammer M; Harrison C; Hehlmann R; Kiladjian JJ; Kröger N; McMullin MF; Passamonti F; Vannucchi A; Barbui T
    Leukemia; 2017 Apr; 31(4):882-888. PubMed ID: 27740634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.